Urokinase / PLAU ( activated by trypsin ) Protein Price Inquiry ( Available Sizes )
Urokinase / PLAU ( activated by trypsin ) Protein Product Information
||PLAU ,ATF, UPA, URK, u-PA
||A DNA sequence encoding the human PLAU (NP_002649.1) ( Met 1-Leu 431 ) with a C-terminal polyhistidine tag was expressed. The purified protein was activated by trypsin in vitro.
Urokinase / PLAU ( activated by trypsin ) Protein QC Testing
||> 97 % as determined by SDS-PAGE.
Urokinase / PLAU ( activated by trypsin ) protein
|Measured by its ability to cleave a peptide substrate, N-carbobenzyloxy-Gly-Gly-Arg-7-amido-4-methylcoumarin (Z-GGR-AMC).
The specific activity is > 2000 pmoles/min/μg
||< 1.0 EU per μg of the protein as determined by the LAL method
||Samples are stable for up to twelve months from date of receipt at -70℃
|Predicted N terminal:
||The secreted recombinant human PLAU comprises 422 amino acids with a predicted molecular mass of 46 kDa. As a result of glycosylation and cleavage, rhPLAU migrates as three bands corresponding to the long α chain, β chain and unprocessed full-length PLAU with the molecular mass of 18, 32 and 50 kDa respectively in SDS-PAGE under reducing conditions.
||Lyophilized from sterile PBS, pH7.4
- Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
- Please contact us for any concerns or special requirements.
Urokinase / PLAU ( activated by trypsin ) Protein Usage Guide
||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Urokinase / PLAU ( activated by trypsin ) Protein Related Products & Topics
Urokinase / PLAU ( activated by trypsin ) Protein Description
Plasminogen activator, urokinase, also known as?PLAU and UPA, is a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. The human PLAU is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide (20 residues). The single chain molecule is processed into a disulfide-linked two-chain molecule of different molecular weights. Two forms of the A chain exist, starting at Ser21 (the long form) and Lys156 (the short form). The long and short A chains are unique to the high and low molecular weight forms, respectively. The long A chain contains an EGF-like domain, responsible for binding of the PLAU receptor. The B chain corresponds to the catalytic domain. PLAU is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium. A specific polymorphism in PLAU gene is implicated in late-onset Alzheimer disease and also with decreased affinity for fibrin-binding.
- Nagai, M. et al., 1985, Gene. 36:183-188.
- Jacobs, P. et al., 1985, DNA. 4:139-146.
- Geiger, M. et al., 1989, Blood. 74 (2): 722-728.
- Ploug, M. et al., 2002, Biochem. Soc. Trans. 30 (2): 177–183.
- Duffy, M.J., 2002, Biochem. Soc. Trans. 30: 207-210.
- Alfano, M. et al., 2004, J. Leukoc. Biol. 74 (5): 750–756.
uPA/Urokinase related areas, pathways, and other information